IMI launches antibiotic research program

The EU's Innovative Medicines Initiative launched the NewDrugs4BadBugs grant program to fund development of new antibiotics against antibiotic-resistant bacteria, including products from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

Read the full 261 word article

How to gain access

Continue reading with a
two-week free trial.